# US 2018/0092815 A1 · Polymerizable quantum dot nanoparticles and their use as therapeutic, ablation and tattooing agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0092815 A1
- Document ID: US20180092815A1
- Status: Published application
- Kind: A1
- Application number: 15/718,239
- Filed: 2017-09-28
- Published: 2018-04-05
- Earliest claimed: 2016-10-04
- Assignees: Nanoco Technologies Ltd.
- Applicants: Nanoco Technologies Ltd.
- Inventors: Imad Naasani; Mark Saunders
- Web page: https://patentgrep.com/patent/US20180092815A1

## CPC

- A61K 8/19: containing inorganic ingredients
- A61K 8/0245: {Specific shapes or structures not provided for by any of the groups of A61K8/0241}
- A61K 8/8152: {Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers}
- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- A61K 41/0042: {Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}
- A61K 41/008: {Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 49/0067: {quantum dots, fluorescent nanocrystals}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 1/025: {Semi-permanent tattoos, stencils, e.g. "permanent make-up"}
- A61K 2800/434: Luminescent, Fluorescent; Optical brighteners; Photosensitizers
- A61K 2800/614: By macromolecular compounds
- A61K 2800/622: by organic compounds
- A61K 2800/81: Preparation or application process involves irradiation
- A61K 2800/95: Involves in-situ formation or cross-linking of polymers
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 40/00: Manufacture or treatment of nanostructures
- Y10S 977/774: Exhibiting three-dimensional carrier confinement, e.g. quantum dots
- Y10S 977/892: Liquid phase deposition
- Y10S 977/897: Polymerization
- Y10S 977/911: Cancer cell destruction
- Y10S 977/926: Topical chemical, e.g. cosmetic or sunscreen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present disclosure relates to quantum dot nanoparticles conjugated to ligands, and in particular quantum dot nanoparticles wherein each nanoparticle is conjugated to a polymerizable ligand. The present disclosure also relates to methods of making such conjugated quantum dot nanoparticles, and the use of such conjugated quantum dot nanoparticles as therapeutic agents, ablation agents and tattooing agents.

## Claims

### Claim 1

A quantum dot nanoparticle conjugate, wherein the nanoparticle is linked to a polymerizable ligand.

### Claim 2 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein the quantum dot nanoparticle comprises:
a core semiconductor material, and
an outer layer,
wherein the outer layer comprises a functionalization organic coating linked to a polymerizable ligand.

### Claim 3 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein the polymerizable ligand is selected from the group consisting of acrylates, methacrylates, diacetylene, cyanoacrylates, azide/alkyne pairs, and any combination thereof.

### Claim 4 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein the polymerizable ligand comprises acrylates and methacrylates.

### Claim 5 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein the polymerizable ligand is a cyanoacrylate.

### Claim 6 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein the polymerizable ligand is a diacetylene.

### Claim 7 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1 wherein the polymerizable ligand is polymerized by a chemical or physical action.

### Claim 8 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein each quantum dot nanoparticle comprises a II-VI material, a III-V material, a I-III-VI material, or any alloy or doped derivative thereof.

### Claim 9 (depends on 1)

The quantum dot nanoparticle conjugate of claim 1, wherein the quantum dot nanoparticle further comprises a cellular uptake enhancer, a tissue penetration enhancer, or a combination thereof.

### Claim 10 (depends on 1)

A method of inducing cell death comprising
i) contacting a quantum dot nanoparticle conjugate according to claim 1 with a cell;
ii) triggering polymerization of the polymerizable ligand using a chemical or physical action.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cell death is induced upon polymerization and affected tissue is visualized.

### Claim 12 (depends on 1)

A method of treating and visualizing a tumor comprising
i) contacting a quantum dot nanoparticle conjugate according to claim 1 with a tumor;
ii) triggering polymerization of the polymerizable ligand using a chemical or physical action.

### Claim 13 (depends on 1)

A method of ablating unwanted tissue comprising
i) contacting a quantum dot nanoparticle conjugate according to claim 1 with unwanted tissue;
ii) triggering polymerization of the polymerizable ligand using a chemical or physical action

### Claim 14 (depends on 13)

The method of claim 13, wherein the unwanted tissue is selected from varicose veins, telangiectasia, and spider nevus.

### Claim 15 (depends on 1)

The use of a quantum dot nanoparticle conjugate according to claim 1 for inducing cell death upon polymerization.

### Claim 16 (depends on 1)

The use of a quantum dot nanoparticle conjugate according to claim 1 for inducing cell death upon polymerization and imaging affected tissues.

### Claim 17 (depends on 1)

The use of a quantum dot nanoparticle conjugate according to claim 1 for the visualization and treatment of malignant and benign tumors.

### Claim 18 (depends on 1)

The use of a quantum dot nanoparticle conjugate according to claim 1 for the visualization and treatment of soft and solid tumors.

### Claim 19 (depends on 1)

The use of a quantum dot nanoparticle conjugate according to claim 1 for cosmetic tattooing.

### Claim 20 (depends on 1)

The use of a quantum dot nanoparticle conjugate according to claim 1 for ablating unwanted tissue, varicose veins, telangiectasia, and spider nevus.
